Dialysis-associated hypertension treated with Telmisartan--DiaTel: a pilot, placebo-controlled, cross-over, randomized trial.
<h4>Unlabelled</h4>Treatment of hypertension in hemodialysis (HD) patients is characterised by lack of evidence for both the blood pressure (BP) target goal and the recommended drug class to use. Telmisartan, an Angiotensin receptor blocker (ARB) that is metabolised in the liver and not...
Main Authors: | Matthias Huber, Till Treutler, Peter Martus, Antje Kurzidim, Reinhold Kreutz, Joachim Beige |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24260194/?tool=EBI |
Similar Items
-
Effect of telmisartan in combined with L-carnitine on peritoneal dialysis patients
by: Effect of telmisartan in combined with L-carnitine on peritoneal dialysis patients, et al.
Published: (2016-07-01) -
Effect of telmisartan combined with levocarnitine on nutritional status in patients with peritoneal dialysis
by: Jin-Xiu Cheng, et al.
Published: (2016-10-01) -
A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial.
by: Jordan E Lake, et al.
Published: (2013-01-01) -
Telmisartan and cardioprotection
by: McFarlane S
Published: (2011-11-01) -
Effects of telmisartan in combined with L-carnitine on the oxidative stress and micro-inflammation status in peritoneal dialysis patients
by: Jin-Xiu Cheng, et al.
Published: (2016-06-01)